Navigation Links
PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business

BOSTON, April 2, 2008 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, today announced that Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P., and Malek Bajbouj, M.D., have been appointed as Vice Presidents of Clinical Pharmacology Consulting Services in the Company's international clinical pharmacology business. These leading experts advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including in regard to psychiatry, neuropsychopharmacology, and neurophysiology clinical studies. Dr. Ereshefsky is based at PAREXEL's Clinical Pharmacology Research Unit in Los Angeles, California in the United States and Dr. Bajbouj is based at the unit in Berlin, Germany.

"Clients increasingly rely on our experts to help identify and select the most promising compounds in the Phase I and Proof of Concept stages. These decisions are based on demonstrating safety and signals of efficacy as early as possible in the drug development process," said Herman Scholtz, M.D., Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "We expect that the extensive medical and scientific expertise Dr. Ereshefsky and Dr. Bajbouj bring to our clinical pharmacology business will further strengthen our central nervous system capabilities in order to help biopharmaceutical companies address growing complexity in this important area of early phase clinical development."

Dr. Larry Ereshefsky is Board Certified in Psychiatric Pharmacy, and has more than 28 years of experience in the neuropsychopharmacology and psychiatry fields. His expertise includes all phases of clinical research and psychopharmacological evaluations of medications for the treatment of a broad range of CNS and psychiatry disorders. Dr. Ereshefsky is a leader in CNS clinical study design and research methodologies, and has served on U.S. Food and Drug Administration (FDA) and United States Pharmacopeia (USP) advisory boards. Prior to joining PAREXEL, Dr. Ereshefsky was Chief Scientific Officer at California Clinical Trials. He was formerly Professor of Psychiatry and Pharmacology at The University of Texas Health Science Center in San Antonio, Texas in the United States. Previously, he was Associate Director of Research at San Antonio State Hospital, and held principal investigator and clinical consulting positions at several medical institutions. Dr. Ereshefsky received a Pharm.D. degree from the University of Southern California (USC), and completed his residency at the Los Angeles County-USC Medical Center. He currently serves on the Executive Committee of The International Society for CNS Clinical Trials and Methodology, and has served as Presidential Officer of the College of Psychiatric and Neurological Pharmacists. He is a frequent presenter, has authored more than 100 articles, and has held editorial advisory positions for major psychiatry, pharmacologic, and psychiatric pharmacy publications.

Dr. Malek Bajbouj is Board Certified in Psychiatry and Clinical Neurophysiology. He has expertise in CNS biomarkers and the development of new physiological procedures, including neurophysiological and neuroimaging measures used in cognitive function research. His research background also includes genetics, antidepressive stimulation techniques, and sleep medicine. Dr. Bajbouj is a Professor at the Charite University in Berlin, Germany, where he heads the Electroencephalography Lab and Neuromodulation Unit. He also serves as Co-Director of the Affective Disorder Module and the Sleep Laboratory at the university. Dr. Bajbouj is a permanent member of the university's Drug Commission and Doctoral Commission. He holds several professional memberships, including the Society of Biological Psychiatry. Dr. Bajbouj serves on the editorial boards of several scientific journals including The American Journal of Psychiatry, Experimental Neurology, and The Open Neuroscience Journal. He has been published extensively in the fields of neurophysiology, neuroimaging, neuromodulation, sleep medicine, and genetics.

In addition to the units noted above, PAREXEL's other Clinical Pharmacology Research Units are located in San Diego, California in the United States; London, United Kingdom; and Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India.

For more information about PAREXEL's international clinical pharmacology capabilities, visit:

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


Jennifer Baird, Director of Public Relations Rebecca Passo

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel: +617-681-1817

Email: Email:

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
2. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
4. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
5. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
6. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
7. PAREXEL International Announces 2-For-1 Stock Split
8. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
Post Your Comments:
(Date:10/12/2017)... ca (PRWEB) , ... October 12, 2017 , ... ... the Surgical Wound Market with the addition of its newest module, US Hemostats ... $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):